“…The structure-based design of small molecules that can stabilize or disrupt helix-protein interactions with high specificity and efficacy is a central challenge in medicinal chemistry. Small molecules which can present functional groups on a pre-organized framework have been identified that disrupt the helix-protein recognition surfaces in interactions such as p53/hDM2 (Prabhakaran, Barnard, et al, 2013; Yin, Lee, et al, 2005), Bak/Bcl-x L (Ernst, Becerril, et al, 2003), and the six helix-bundle assembly of GP41 (Ernst, Kutzki, et al, 2002). Plainly, helix-protein interactions are an important and addressable category of biological target.…”